Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain

Aguilar, Isabel Miras; Reyes, Michele; Martínez‐Baz, Iván; Guevara, Marcela; Albéniz, Esther; Belza, María José

doi:10.2807/ese.17.17.20154-en

Cited by 45 publications

(49 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients aged ≥65, who accounted for around one third of our sample, VC were above 70% for the influenza seasonal vaccines for both seasons, similar (76%) to that reported in another study among patients of the French GPs in 2006–2007 season [10], but substantially higher than VC value (61%) estimated in general population aged 65 and over in France in 2010–2011 season [11], in Spain in 2010–2011 (59%) and 2009–2010 (63%) [12], and in the United States in 2009–2010 (69%) [13]. In our sample of cardiovascular disease sufferers, VC varied notably between the two age groups: 43-47% below the age of 65, and 83-85% above 65.…”

Section: Discussionsupporting

confidence: 89%

Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional study among patients of the French Sentinelles general practitioners

et al. 2013

View full text Add to dashboard Cite

BackgroundThree main categories of persons are targeted by the French influenza vaccination strategy: all persons aged 65 years or over, those aged less than 65 years with certain underlying medical conditions and health care workers. The main objective of this study was to estimate rates of influenza immunization in these target groups attending a medical consultation for two consecutive influenza seasons: 2009–2010 (seasonal and pandemic vaccines) and 2010–2011 (seasonal vaccine).MethodsA standardized questionnaire was mailed to 1323 general practitioners (GPs) of the Sentinelles Network, collecting data on all patients seen on a randomly assigned day. For every patient, following information was collected: age, gender, BMI, presence of any medical condition that increases risk of severe influenza illness, and vaccination status for the three vaccines mentioned.ResultsTwo hundred and three GPs agreed to participate and included 4248 patients. Overall, in persons with high risk of severe influenza, the estimated vaccine coverages (VC) were 60%, (95% CI = 57%; 62%) for the seasonal vaccine in 2010–2011, 61% (59%; 63%) for the seasonal vaccine in 2009–2010 and 23% (21%; 25%), for the pandemic vaccine in 2009–2010. Among people aged 65 years and over (N=1259, 30%) VC was estimated for seasonal vaccines at 72% (70%; 75%) in 2010–2011 and 73% (71%; 76%) in 2009–2010, and 24% (22%; 26%) for the pandemic vaccine. The lowest seasonal VC were observed in younger persons (<65 years) with underlying medical conditions, in particular pregnant women (<10%) and overweight persons (<30%).ConclusionsOur study shows that influenza vaccination coverage among patients of the French Sentinelles general practitioners remains largely below the target of 75% defined by the 2004 French Public Health Law, and underscores the need for the implementation of public health interventions likely to increase vaccination uptake.

show abstract

Section: Discussionsupporting

confidence: 89%

Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional study among patients of the French Sentinelles general practitioners

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Precise instructions for registering each dose of vaccine were communicated to all vaccination sites [7]. Influenza vaccine status was obtained from the online regional vaccination register [8] and people were considered to be protected 14 days after vaccine administration. Those for whom the period between vaccination and symptom onset was less than 14 days were excluded, as their immune status is unknown.…”

Section: Setting and Information Sourcesmentioning

confidence: 99%

Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis

et al. 2014

Self Cite

View full text Add to dashboard Cite

We estimate mid-2013/14 season vaccine effectiveness (VE) of the influenza trivalent vaccine in Navarre, Spain. Influenza-like illness cases attended in hospital (n=431) and primary healthcare (n=344) were included. The overall adjusted VE in preventing laboratory-confirmed influenza was 24% (95% CI: −14 to 50). The VE was 40% (95% CI: −12 to 68) against influenza A(H1)pdm09 and 13% (95% CI: −36 to 45) against influenza A(H3). These results suggest a moderate preventive effect against influenza A(H1)pdm09 and low protection against influenza A(H3).

show abstract

“…The vaccination status for the trivalent 2010–2011 seasonal influenza vaccine and monovalent A(H1N1)pdm09 influenza vaccine was obtained from the online regional vaccination register [18]. Subjects were considered to be protected 14 days after vaccine administration.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case–control study

et al. 2013

View full text Add to dashboard Cite

BackgroundSome studies have evaluated vaccine effectiveness in preventing outpatient influenza while others have analysed its effectiveness in preventing hospitalizations. This study evaluates the effectiveness of the trivalent influenza vaccine in preventing outpatient illness and hospitalizations from laboratory-confirmed influenza in the 2010–2011 season.MethodsWe conducted a nested case–control study in the population covered by the general practitioner sentinel network for influenza surveillance in Navarre, Spain. Patients with influenza-like illness in hospitals and primary health care were swabbed for influenza testing. Influenza vaccination status and other covariates were obtained from health care databases. Using logistic regression, the vaccination status of laboratory-confirmed influenza cases was compared with that of test-negative controls, adjusting for age, sex, comorbidity, outpatient visits in the previous 12 months, health care setting, time between symptom onset and swabbing, period and A(H1N1)pdm09 vaccination. Effectiveness was calculated as (1-odds ratio)x100.ResultsThe 303 confirmed influenza cases (88% for A(H1N1)pdm09 influenza) were compared with the 286 influenza test-negative controls. The percentage of persons vaccinated against influenza was 4.3% and 15.7%, respectively (p<0.001). The adjusted estimate of effectiveness was 67% (95% CI: 24%, 86%) for all patients and 64% (95% CI: 8%, 86%) in those with an indication for vaccination (persons age 60 or older or with major chronic conditions). Having received both the 2010–2011 seasonal influenza vaccine and the 2009–2010 pandemic influenza vaccine provided 87% protection (95% CI: 30%, 98%) as compared to those not vaccinated.ConclusionThe 2010–2011 seasonal influenza vaccine had a moderate protective effect in preventing laboratory-confirmed influenza.

show abstract

Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain

Abstract: Binary file ES_Abstracts_Final_ECDC.txt matches

Cited by 45 publications

References 17 publications

Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional study among patients of the French Sentinelles general practitioners

Rates of immunization against pandemic and seasonal influenza in persons at high risk of severe influenza illness: a cross-sectional study among patients of the French Sentinelles general practitioners

Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis

Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010–2011: a population-based test-negative case–control study

Contact Info

Product

Resources

About